Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Chief Strategy Officer | March 15, 2024 | March 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date March 15, 2024 · Filed March 29, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,914 |
Reported balance
After 2024-03-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 30,000 · Balance 31,914 F1: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 18, 2024 23:28 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000167 · form4.xml · derivative · entry 2 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-14 F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:28 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000167 · form4.xml · nonDerivative · entry 1 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,914 F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 15, 2024 Filed Mar 29, 2024 20:17 UTC Amendment | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000193 · form4.xml · nonDerivative · entry 1 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,914 F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| January 09, 2024 Filed Jan 12, 2024 00:59 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0001610717-24-000027 · form4.xml · derivative · entry 5 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,832 Underlying: Common Stock · 5,000 shares Expires 2031-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| January 09, 2024 Filed Jan 12, 2024 00:59 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Exercise / conversionStock Option (right to buy) · Derivative | 2,417 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001610717-24-000027 · form4.xml · derivative · entry 4 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,868 Underlying: Common Stock · 2,417 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. F3 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| January 09, 2024 Filed Jan 12, 2024 00:59 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 7,417 | $20.14 | $149,367.25 |
DisclosureSEC source: 0001610717-24-000027 · form4.xml · nonDerivative · entry 3 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,914 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2024 Filed Jan 12, 2024 00:59 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Exercise / conversionCommon Stock | 5,000 | $6.60 | $33,000.00 |
DisclosureSEC source: 0001610717-24-000027 · form4.xml · nonDerivative · entry 2 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. Read SEC document |
| January 09, 2024 Filed Jan 12, 2024 00:59 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Exercise / conversionCommon Stock | 2,417 | $0.42 | $1,015.14 |
DisclosureSEC source: 0001610717-24-000027 · form4.xml · nonDerivative · entry 1 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:06 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Exercise / conversionStock Option (right to buy) · Derivative | 2,583 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001610717-24-000014 · form4.xml · derivative · entry 3 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,285 Underlying: Common Stock · 2,583 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. F5 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:06 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,583 | $20.12 | $51,967.12 |
DisclosureSEC source: 0001610717-24-000014 · form4.xml · nonDerivative · entry 2 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,914 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. F4 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.26. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:06 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Exercise / conversionCommon Stock | 2,583 | $0.42 | $1,084.86 |
DisclosureSEC source: 0001610717-24-000014 · form4.xml · nonDerivative · entry 1 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. F2 · balance_after: Reflects the adjusted total which includes the purchase of 934 shares under the AN2 Employee Stock Purchase Plan on March 31, 2023. F3 · balance_after: Reflects the adjusted total which includes the purchase of 980 shares under the AN2 Employee Stock Purchase Plan on September 29, 2023. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 62,200 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0000899243-23-005545 · doc4.xml · derivative · entry 1 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,200 Underlying: Common Stock · 62,200 shares Expires 2033-02-14 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:16 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 66,000 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018278 · doc4.xml · derivative · entry 1 Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.